MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Procedural Memory Changes of Parkinson’s Disease Patients Post Participation in Boxing

    A. Ghaffar, R. Gallagher, C. Mcleod, A. Leder (Old Westbury, NY, USA)

    Objective: Can participation in a Rock Study Boxing program improve procedural memory in people with Parkinson’s disease (PD)? Background: Procedural memory is important for daily…
  • 2019 International Congress

    Neuropsychological changes over the first 6 years of Parkinson’s disease in the ICICLE-PD cohort

    R. Lawson, G. Duncan, T. Khoo, D. Breen, M. Camacho, C. Williams-Gray, R. Barker, L. Rochester, D. Burn, A. Yarnall (Newcastle Upon Tyne, United Kingdom)

    Objective: To determine the longitudinal differences in cognitive tests in participants with Parkinson’s disease (PD), and the neuropsychological tests most sensitive to change over and…
  • 2019 International Congress

    Plasma Soluble ST2 (sST2) levels are Higher in Neurodegeneration and Associate with PD Cognition

    ASL. Ng, YJ. Tan, ACW. Yong, BYX. Wong, ZH. Lu, SYE. Ng, SKS. Ting, S. Hameed, L. Zeng, N. Kandiah, WL. Au, LCS. Tan (Singapore, Singapore)

    Objective: As plasma IL-33 levels are too low to accurately quantify, we measured plasma sST2 as a surrogate marker for IL-33 in samples from healthy…
  • 2019 International Congress

    Cognitive impairment in Parkinson’s Disease: A cross-sectional association study

    A. Simon, C. Rodriguez-Blazquez, MJ. Forjaz, P. Martinez-Martin (Madrid, Spain)

    Objective: To characterize the presence and clinical presentation of PD-MCI and PDD in patients with idiopathic PD, examining motor and non-motor features and determining factors…
  • 2019 International Congress

    Predicting DRS-2 Total scores from the MoCA

    M. Zorn, K. Duff, J. Rolston, J. Ballard, C. Aquino, P. Moretti (Salt Lake City, UT, USA)

    Objective: Evaluate whether the Montreal Cognitive Assessment (MoCA) score is predictive of Dementia Rating Scale - 2 (DRS-2) score in the clinical evaluation of deep brain stimulation (DBS) candidates, in an…
  • 2019 International Congress

    Dorsolateral striatal neuronal activity in a rat model of Parkinson`s disease with levodopa-induced dyskinesias

    X. Jin, D. Milakara, K. Schwabe, J. Krauss, M. Alam (Nanjing, China)

    Objective: This study aimed to investigate the firing properties of fast spiking interneurons (FSIs) and medium spiny neurons (MSNs) of the dorsomedial striatum (DLStr) and…
  • 2019 International Congress

    Widespread distribution and abundant accumulation of alpha-synuclein oligomers in multiple system atrophy brain

    H. Sekiya, H. Kowa, H. Koga, M. Takata, W. Satake, N. Futamura, I. Funakawa, K. Jinnai, M. Kanagawa, K. Kobayashi, T. Toda (Kobe, Japan)

    Objective: To examine the distribution of alpha-synuclein (αSyn) oligomers as an early pathological change in multiple system atrophy (MSA) brains. Background: Although severe neuronal loss…
  • 2019 International Congress

    Establishing the first apomorphine treatment registry in Thailand: prospective data collection to inform optimal care of Parkinson’s disease patients

    R. Bhidayasiri, O. Phokaewvarangkul, K. Boonpang, T. Boonmongkol, Y. Thongchuam, N. Kantachadvanich, J. Sringean, P. Panyakaew, P. Jagota (Bangkok, Thailand)

    Objective: To establish a registry of PD patients in Thailand treated with subcutaneous apomorphine (APO) injection or infusion to allow prospective data collection from the…
  • 2019 International Congress

    Antipsychotics Use in Parkinson’s Disease and Mortality Risks

    WM. Liu, JH. Wang, HY. Chen, R. Lo (Hualien, Taiwan)

    Objective: To describe the use of antipsychotics in patients with Parkinson’s disease (PD) and study its associated mortality risks. Background: The US Food and Drug…
  • 2019 International Congress

    Prevalence of Parkinsonian Syndrom in the World

    MRS. Sabirova (Tashkent, Uzbekistan)

    Objective: To study epidemiological condition of Parkinson disease in the world. Background: Parkinson's disease (PD) is a long-term degenerative disorder  of the central nervous system…
  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley